Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Emergent BioSolutions Q3 Revenue Declines to $110 Million Amid Contract Shifts

Emergent BioSolutions saw a significant revenue contraction in the third quarter of 2026, leading to a net loss of $32.70 million. The company is currently navigating a restructuring of its debt obligations and a leadership transition in its finance department while managing key government contracts.

Apothecary, pharmacy, chemist, mortar and pestle. Stock photo illustrating Emergent BioSolutions' financial results story.
Emergent BioSolutions Inc. · Photo: stevepb / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 110.00231.10
Pretax Income -36.4057.60
Net Income -32.7051.20
Diluted EPS -0.640.91
Net Income YoY
-163.9%

Key highlights

  • Quarterly revenue fell to $110.00 million from $231.10 million in the prior year
  • Net income declined 163.9% year-over-year to a loss of $32.70 million
  • Diluted earnings per share dropped to -$0.64 compared to $0.91 in Q3-2025
  • Total assets decreased to $995.2 million from $1,318.6 million at year-end 2025
  • The company is operating under a new 2026 Term Loan Agreement to manage debt

How the Period Went

Emergent BioSolutions reported total revenue of $110.00 million for the third quarter of 2026, marking a significant decline from the $231.10 million recorded in the same period last year. This sharp drop in top-line performance directly impacted the bottom line, resulting in a net loss of $32.70 million compared to a net income of $51.20 million in Q3-25. Diluted earnings per share shifted from $0.91 to -$0.64 year-over-year. The 163.9% decrease in net income underscores a challenging quarter as the company navigates shifts in its medical countermeasure contract timing and commercial product distribution cycles.

Margins and Profitability

The company experienced a substantial swing in profitability, with pretax income falling to a loss of $36.40 million from a profit of $57.60 million in the prior year. This margin compression occurred as the company managed significant debt obligations under its 2026 Term Loan Agreement. Total assets also contracted to $995.2 million as of September 30, 2026, down from $1,318.6 million at the end of 2025. Financial stability efforts are currently centered on optimizing the cost structure and addressing satisfied performance obligations, which stood at $268.7 million earlier in the year according to SEC filings.

Business Overview

Emergent BioSolutions operates as a specialty pharmaceutical firm specializing in public health preparedness. The company’s business model is bifurcated between medical countermeasure (MCM) contracts with the U.S. government and commercial healthcare products. Its MCM portfolio includes vaccines and therapeutics targeting biological and chemical threats, while its commercial segment is led by NARCAN Nasal Spray for opioid overdose reversal. By serving both federal defense needs and the generic drug market, the company maintains a unique position at the intersection of national security and public health, though it remains sensitive to government procurement timelines.

Financial Context

In the context of recent performance, the $110.00 million in Q3 revenue represents a sequential decline from $234.3 million in Q2 2026 and $156.1 million in Q1 2026, based on reports from GlobeNewswire and Emergent BioSolutions. With a market capitalization of approximately $330.2 million and a share price of $6.44, the stock has faced an 11.29% decline over the past quarter. The Relative Strength Index of 46.7 suggests the equity is trading in a neutral technical range. Investors are also monitoring the company's $50 million share repurchase program, which remains active until March 2027.

Emergent BioSolutions Inc. share price · last month
Line chart of Emergent BioSolutions Inc.'s share price over the last month, from $6.36 on 19 Oct → $5.81 on 16 Nov; our story on 3 Nov at $6.44.

Down 9.8% since our story on 3 Nov: $6.44 when we broke it → $5.81 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$6.36
20 Oct$6.29
21 Oct$6.20
22 Oct$6.23
23 Oct$6.23
26 Oct$6.34
27 Oct$6.67
28 Oct$7.09
29 Oct$7.22
30 Oct$6.81
2 Nov$6.44
3 Nov$6.25
4 Nov$5.90
5 Nov$5.85
6 Nov$6.06
9 Nov$6.10
10 Nov$6.05
11 Nov$6.04
12 Nov$5.89
13 Nov$5.79
16 Nov$5.81

Industry Landscape

The specialty drug manufacturing sector is currently navigating a period of stabilization following post-pandemic demand shifts. Peers such as SIGA Technologies and Bavarian Nordic, which also provide biodefense solutions, face similar lumpy revenue patterns dictated by government stockpiling cycles. Within the broader healthcare sector, Emergent’s transition is marked by executive changes, including the upcoming retirement of CFO Richard S. Lindahl in December 2026, according to StockTitan. As the industry shifts toward more resilient supply chains, Emergent’s focus on the 2026 Term Loan Agreement and its medical countermeasure pipeline remains critical for competitive positioning against generic manufacturers.

Recent quarters and guidance
DateAnnouncementAmount
02 Nov 2026Q3 2026 total revenuesSource: stocktitan.net$110.0 Million
05 Aug 2026Q2 2026 total revenuesSource: globenewswire.com$234.3 Million
30 Apr 2026Q1 2026 total revenuesSource: investors.emergentbiosolutions.com$156.1 Million
26 Feb 2026Q4 2025 total revenuesSource: SEC filing$148.7 Million
29 Oct 2025Q3 2025 total revenuesSource: investors.emergentbiosolutions.com$231.1 Million
06 Aug 2025Q2 2025 total revenuesSource: biospace.com$140.9 Million
Emergent BioSolutions Inc. · financial snapshot
Share price$6.44
Market cap$330M
Revenue (annual)$705M
1-month price change+1.10%
SectorHealthcareDrug Manufacturers - Specialty & Generic

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Emergent BioSolutions Inc. announcing its third quarter 2026 financial results.

Read the filing ↗

Track Emergent BioSolutions Inc. live

Get the next Emergent BioSolutions Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.